海正药业(600267.SH)：替加环素原料药获得CEP证书

Core Viewpoint - The company, Haizheng Pharmaceutical, has received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP certificate) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Tigecycline active pharmaceutical ingredient [1] Group 1 - The CEP certificate indicates that Tigecycline is suitable for use in treating infections caused by specific sensitive strains of bacteria in patients aged 18 and above [1] - Tigecycline is primarily indicated for the treatment of complex intra-abdominal infections, complex skin and soft tissue infections, and community-acquired bacterial pneumonia [1]